Results 1 to 10 of about 12,151 (168)

Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients [PDF]

Thoracic Cancer
Background Second‐generation anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and brigatinib, are widely used in patients with ALK‐positive non‐small cell lung cancer (NSCLC) who develop resistance or progress on crizotinib. However, real‐
Min Jee Kim, Hyun Seok Kwak, Eun Nim Koh, Cheol‐Kyu Park, Young‐Chul Kim, In‐Jae Oh, Seung Joon Kim, Jun Hyeok Lim, Jeong‐Seon Ryu, Chang Min Choi   +9 more
doaj   +2 more sources

In Vitro and In Vivo Evaluation of Alectinib-Loaded Dendrimer Nanoparticles as a Drug Delivery System for Non-Small Cell Lung Carcinoma [PDF]

Pharmaceutics
Background/Objectives: Alectinib, a second-generation tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer (NSCLC), exhibits suboptimal oral bioavailability, primarily attributable to its inherently low aqueous solubility ...
Mahmood R. Atta, Israa Al-Ani, Ibrahim Aldeeb, Khaldun M. AlAzzam, Tha’er Ata, Mohammad A. Almullah, Enas Daoud, Feras Al-Hajji   +7 more
doaj   +2 more sources

Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China [PDF]

Oncology and Therapy
Introduction Brigatinib and alectinib are anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs) approved in China in 2022 and 2018, respectively, for the treatment of patients with ALK-positive, advanced non‑small‑cell lung cancer (NSCLC)
Qingqing Chai, Congling Gu, Luis Hernandez, Yan-Jun Zhang   +3 more
doaj   +2 more sources

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

Case Reports in Oncology, 2021
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib.
Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, Shoichi Kuyama   +4 more
doaj   +1 more source

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report

Journal of Medical Case Reports, 2022
Background Targeted therapy with anaplastic lymphoma kinase inhibitor alectinib has become standard therapy for selected patients with non-small cell lung carcinoma. Few data are available on the renal effects of alectinib.
Marco van Londen, Elizabeth Roosma, Stefanie Vogels, John W. G. van Putten, Wilbert M. T. Janssen   +4 more
doaj   +1 more source

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

JTO Clinical and Research Reports, 2023
Introduction: Alectinib was found to have superior efficacy to crizotinib in the phase 3 ALEX study and is a preferred initial treatment for patients with advanced ALK-positive NSCLC. To understand the efficacy of alectinib in U.S.
Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD   +9 more
doaj   +1 more source

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

Cancer Reports, 2021
Background Most patients treated with anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitors for ALK‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous system (CNS) being a ...
Hiroaki Sakamoto, Noriko Yanagitani, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Sadatomo Tasaka, Makoto Nishio   +12 more
doaj   +1 more source

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. [PDF]

, 2020
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Al-Holou, Wajd, Armas, Octavio, Kubota, Takafumi, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Raval, Kunil, Robinette, Natasha, Zhu, Viola W   +7 more
core   +1 more source

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer

Diagnostics, 2022
Companion diagnostic tests and targeted therapy changed the management of non-small cell lung cancer by diagnosing genetic modifications and enabling individualized treatment.
Sulim Kang, Jaehyun Woo, Sungmin Kim
doaj   +1 more source

High incidence and reversible bradycardia events following alectinib initiation

Thoracic Cancer, 2023
Background With the widespread use of alectinib in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC), its cardiotoxicity has gradually emerged, including new‐onset sinus bradycardia (SB).
Dongqi Yuan, Fuyi Zhu, Ran Zuo, Yu Wang, Gengwei Huo, Jinfang Cui, Ping Yue, Peng Chen   +7 more
doaj   +1 more source